AN2 Therapeutics, Inc. (ANTX) stock
ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.95+0.72 (+17.02%)
Close on Nov 18, 2026Market cap $186.79MP/E –Yield –
AN2 Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
AN2 Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$38.81M. For fiscal 2025 it was -$38.11M. The highest annual figure on record is -$21.57M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.11M | – |
| FY2024 | Dec 31, 2024 | -$56.79M | – |
| FY2023 | Dec 31, 2023 | -$69.64M | – |
| FY2022 | Dec 31, 2022 | -$42.26M | – |
| FY2021 | Dec 31, 2021 | -$21.57M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.55M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.32M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.04M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.60M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.01M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.88M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$16.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.04M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.48M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.77M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.33M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.59M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.05M | – |
See a number that looks wrong?